Skip to content
Sunday, April 05, 2026

TrialistMD

Clarity in Trials, Confidence in Decisions

  • Home
  • Clinical trials
    • Dermatology
    • Rare disease
    • Cardiology
    • Metabolic
    • Nephrology
    • Oncology
      • Breast
      • Gastrointestinal
      • Head and Neck Carcinoma
      • Hepatic
      • Lung Carcinoma
      • Renal
      • Genitourinary
  • FDA Approved Drugs
    • 2021 Approval
    • 2022 Approval
    • 2023 Approval
    • 2024 Approval
    • 2025 Approval
    • 2026 Approval
  • About us
  • 📞 Contact Us
You are Here
  • Home
  • Clinical trials
  • Dermatology
  • Page 2

Category: Dermatology

Bimekizumab
Dermatology

Bimekizumab

March 29, 2026March 29, 2026

FDA Approved · October 2023 IL-17A & F Inhibitor · Dermatology · Plaque Psoriasis ⚠

Difamiliast
Dermatology

Difamiliast

March 27, 2026March 29, 2026

FDA Approved · February 2026 PDE-4 Inhibitor · Dermatology · Atopic Dermatitis Difamilast ADQUEY™ ·

Deuruxolitinib
Dermatology

Deuruxolitinib

March 26, 2026March 29, 2026

Deuruxolitinib (LEQSELVI) — TrialistMD Drug Profile TRIALISTMD · Drug Intelligence Platform FDA APPROVED 2024 JAK

« Prev 1 2
  • 📞 Contact Us
  • About us
  • Privacy
All Rights Reserved 2026.
Proudly powered by WordPress | Theme: Nhuja News by Candid Themes.